Table 1 Patients’ characteristics and treatment modalities
Variable | ||
|---|---|---|
Age | Median (range) | 57.0 (34.3–79.9) |
Body mass index (BMI) | Median (range) t0 a | 25.0 (18.7–63.5) |
Median (range) t1 a | 25.5 (16.4–65.3) | |
pT stage | Number of patients (%) | |
I | 97 (48.5%) | |
II | 95 (47.5%) | |
III | 4 (2.0%) | |
IV | 3 (1.5%) | |
pN stage | ||
1 | 165 (82.5%) | |
2 | 28 (14.0%) | |
3 | 7 (3.5%) | |
Grading | ||
1 | 13 (6.5%) | |
2 | 144 (57.0%) | |
3 | 69 (34.5%) | |
Tumor size (mm) | Median (range) | 19 (0–90) |
Resection volume (g) | Median (range) | 50 (5–931) |
Resected lymph nodes (n) | Median (range) | 17.5 (2–55) |
Involved lymph nodes (n) | Median (range) | 2 (0–22) |
Hormone therapy | Number of patients (%) | |
Yes | 152 (76.0%) | |
No | 43 (21.5%) | |
Chemotherapy | Total | |
yes | 156 (78.0%) | |
no | 44 (22.0%) | |
Adjuvant | ||
Yes | 133 (66.5%) | |
No | 67 (33.5%) | |
Neoadjuvant | ||
Yes | 23 (11.5%) | |
No | 177 (88.5%) | |
Radiation volume | Breast | |
yes | 200 (100%) | |
SCRT | ||
Yes | 75 (37.5%) | |
No | 125 (62.5%) | |
Boost (breast) | ||
Yes | 65 (32.5%) | |
No | 135 (67.5%) | |
Follow up (years) | Median (range) | 10.1 (4.9–15.9) |